With a $2.47 million gift from Novo Nordisk Inc., Live HealthSmart Alabama is applying its holistic health model in Selma, ...

Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

The microbial ecosystems within our mouths may affect our cognitive function as we age, according to a study. Interventions such as prebiotics, including dietary nitrate, have potential for delaying ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

China Universal Asset Management Co. Ltd. lessened its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the ...

A daily rundown of the economic reports and corporate earnings that will be grabbing the market’s attention in the week ahead ...